Title :

Buprenorphine dosing choices in specific populations: review of expert opinion

Author(s) :

Maremmani, Icro [Auteur]
Rolland, Benjamin [Auteur]
Somaini, Lorenzo [Auteur]
Roncero, Carlos [Auteur]
Reimer, Jens [Auteur]
Wright, Nat [Auteur]
Littlewood, Richard [Auteur]
Krajci, Peter [Auteur]
Alho, Hannu [Auteur]
D'agnone, Oscar [Auteur]
Simon, Nicolas [Auteur]
Groupe de Recherche sur les formes Injectables et les Technologies Associées - ULR 7365 [GRITA]

Journal title :

Expert opinion on pharmacotherapy

Abbreviated title :

Expert Opin. Pharmacother.

Volume number :

17

Pages :

1727-1731

Publication date :

2016-09-01

ISSN :

1465-6566

English keyword(s) :

special groups
dosing
Buprenorphine
opioid dependence

HAL domain(s) :

Sciences du Vivant [q-bio]

English abstract : [en]

BACKGROUND: Treatment of opioid dependence with buprenorphine improves outcomes. Typical dosing ranges for all patients from clinical evidence and as defined in the product information are wide. For specific groups with ...
Show more >BACKGROUND: Treatment of opioid dependence with buprenorphine improves outcomes. Typical dosing ranges for all patients from clinical evidence and as defined in the product information are wide. For specific groups with complex clinical scenarios, there is no clear consensus on dosing choices to achieve best possible outcomes. METHODS: The doses of buprenorphine used in 6 European countries was reviewed. A review of published evidence supported rapid induction with buprenorphine and the benefits of higher doses but did not identify clearly useful guidance on dosing choices for groups with complex clinical scenarios. An expert group of physicians with experience in addiction care participated in a discussion meeting to share clinical practice experience and develop a consensus on dosing choices. CONCLUSIONS: There was general agreement that treatment outcomes can be improved by optimising buprenorphine doses in specific subgroups. Specific groups in whom buprenorphine doses may be too low and who could have better outcomes with optimised dosing were identified on the basis of clinical practice experience. These groups include people with severe addiction, high tolerance to opioids, and psychiatric comorbidities. In these groups it is recommended to review dosing choices to ensure buprenorphine dosing is sufficient.Show less >

Language :

Anglais

Audience :

Internationale

Popular science :

Non

Administrative institution(s) :

CHU Lille
CNRS
Inserm
Université de Lille

Collections :

• Groupe de Recherche sur les formes Injectables et les Technologies Associées (GRITA) - ULR 7365

Submission date :

2019-11-27T13:36:37Z